🟢 100/100

This product looks safe

  • No ingredients exceed tolerable upper intake levels
  • Limited research evidence available for ingredients
B Label Compliance Grade

Product Label

📸

Have a supplement label? Find it here.

Upload a photo of any supplement label to search our database of 92,312 products.

Label Data

1 Capsule(s) Serving Size
Mineral Product Type
0% Evidence Coverage

Supplement Facts — Evidence Check

Iron
150 mg (833% DV)

Other Ingredients

Sodium Lauryl Sulfate Gelatin Microcrystalline Cellulose Stearic Acid Polyethylene Glycol Citric Acid Croscarmellose Sodium Titanium Dioxide Polyvinylpyrrolidone FD&C Yellow No. 5 Lake FD&C Red No. 40 Lake FD&C Red No. 3 Lake FD&C Blue No. 1 Lake

Label Claims — Verification

Nutrient
All Other
Structure/Function
All Other (99% of products) Structure/Function (71% of products) Nutrient (61% of products) Approved Health (1% of products)

Target Groups

Adult (18 - 50 Years)

Product Information

📋 Directions for Use

Dosage and administration: Adults: One or two capsules daily, or as prescribed by a physician.

⚠️ Warnings & Precautions

Contains FD&C Yellow No. 5 Lake (Tartrazine) as a color additive.

Contraindications: Ferrex 150 is contraindicated in patients with a known hypersensitivity to any of the components of this product. Hemochromatosis and hemosiderosis are contraindications in the use of this dietary supplement.

Precautions: This product contains FD&C Yellow No. 5 Lake (tartrazine), which may cause allergic-type reactions (including bronchial asthma) in certain susceptible persons.

Although the overall incidence of FD&C Yellow No. 5 Lake (tartrazine) sensitivity in the general population is low, it is frequently seen in patients who also have aspirin hypersensitivity.

The type of anemia and the underlying cause or causes should be determined before initiating supplementation with Ferrex 150. Since the anemia may be a result of a systemic disturbance, such as a recurrent blood loss, the underlying cause or causes should be corrected if possible.

Since oral iron products interfere with absorption of certain antibiotics, these products should not be taken within two hours of each other.

As with all oral iron preparations, Ferrex 150 should be stored out of the reach of children to protect against accidental iron poisoning.

Patients should not exceed the recommended dosage unless directed by a physician. Patients should be informed that iron products can cause dark or black stools.

Do not use if blister seals are broken

To Report Serious Adverse Effects Call: 800-616-2471

Warning: Accidental overdose of iron-containing products is a leading cause of fatal poisoning in children under 6. Keep this product out of reach of children. In case of accidental overdose, call a doctor or poison control center immediately.

Adverse reactions: Adverse reactions with iron therapy may include constipation, diarrhea, nausea, vomiting, dark stool and abdominal pain. Adverse reactions with iron therapy are usually transient. Overdose: The clinical cause of acute iron overdose can be variable. Initial symptoms may include abdominal pain, nausea, vomiting, diarrhea, tarry stools, melena, hematemesis, hypotension, tachycardia, metabolic acidosis, hyperglycemic, dehydration, drowsiness, pallor, cyanosis, lassitude, seizures, shock and coma.

Keep this and all medications out of the reach of children.

🧪 Formulation Notes

Ferrex 150 Polysaccharide-Iron complex capsules are a product of ferric iron complexed to a low molecular weight polysaccharide. This polysaccharide is a product of extensive hydrolysis of starch.

As an organic complex, it contains no free irons.

Precautions: This product contains FD&C Yellow No. 5 Lake (tartrazine), which may cause allergic-type reactions (including bronchial asthma) in certain susceptible persons.

Polysaccharide-Iron Complex Capsules

Additional Information

It is tasteless and odorless.

Indications and usage: Ferrex 150 may be used for the dietary management of iron deficiencies.

Re-Order No. 081119 M-29 Rev. 09/11

For dispensing purpose only

10 x 10 Capsules

How supplied: Unit Dose blister packs, 10 capsules per card, orange/brown capsules imprinted B-203.

Store at 25(0)C (77(0)F); excursions permitted to 15(0)-30(0)C (59(0)-86(0)F). See USP Controlled Room Temperature.

N

Product Details

UPC / SKU 3 09045 39561 5
DSLD Entry Date 2019-04-25
Product Type Mineral
Form Capsule
Brand Major
DSLD ID 201596
Data Updated 2026-04-11

Research Evidence

566 Research Sources
56 Avg Quality Score
240 Meta Analysis
100 Clinical Trial
74 Systematic Review
71 Guideline
58 Rct
11 Cochrane Review
4 Regulatory Source
2 Other
2 Narrative Review
1 Observational
1 Openfda Safety
A Systematic review and meta-analysis of intravenous iron therapy for patients with heart failure and iron deficiency
Meta Analysis Nature medicine 2025
A Intermittent iron supplementation for reducing anaemia and its associated impairments in adolescent and adult menstruating women
Meta Analysis The Cochrane database of systematic reviews 2019
A Oral or parenteral iron supplementation to reduce deferral, iron deficiency and/or anaemia in blood donors
Meta Analysis The Cochrane database of systematic reviews 2014
A Serum or plasma ferritin concentration as an index of iron deficiency and overload
Meta Analysis The Cochrane database of systematic reviews 2021
A Non-invasive diagnostic tests for Helicobacter pylori infection
Meta Analysis The Cochrane database of systematic reviews 2018
A Hypoxia-inducible factor stabilisers for the anaemia of chronic kidney disease
Meta Analysis The Cochrane database of systematic reviews 2022
A Wheat flour fortification with iron and other micronutrients for reducing anaemia and improving iron status in populations
Meta Analysis The Cochrane database of systematic reviews 2021
A Fortification of condiments and seasonings with iron for preventing anaemia and improving health
Meta Analysis The Cochrane database of systematic reviews 2023
A Screening and Supplementation for Iron Deficiency and Iron Deficiency Anemia During Pregnancy: US Preventive Services Task Force Recommendation Statement.
Guideline JAMA 2024
A Psychiatric and cognitive outcomes of iron supplementation in non-anemic children, adolescents, and menstruating adults: A meta-analysis and systematic review
Meta Analysis Neuroscience and biobehavioral reviews 2025
View all evidence for Iron →

Compare Similar Products

View all Iron products →